7311-93-5

Usage

Uses

Used in Pharmaceutical Industry:
3-(PIPERIDINE-1-SULFONYL)-BENZOIC ACID is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with specific therapeutic properties. Its structural components allow for the creation of compounds that can target a range of medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 3-(PIPERIDINE-1-SULFONYL)-BENZOIC ACID is utilized as an intermediate in the production of agrochemicals, contributing to the development of compounds that can enhance crop protection and management.
Used in Organic Synthesis:
3-(PIPERIDINE-1-SULFONYL)-BENZOIC ACID is used as a building block in organic synthesis for its capacity to be modified and functionalized, leading to the creation of a variety of organic compounds with different applications across various industries.

InChI:InChI=1/C12H15NO4S/c14-12(15)10-5-4-6-11(9-10)18(16,17)13-7-2-1-3-8-13/h4-6,9H,1-3,7-8H2,(H,14,15)

Upstream product

• 110-89-4 piperidine 
• 4025-64-3 3-Carboxybenzenesulfonyl chloride 
• 65-85-0 benzoic acid 
• 63555-50-0 methyl 3-chlorosulfonylbenzoate 
• 415712-10-6 methyl 3-(piperidin-1-ylsulfonyl)benzoate 

Downstream Products

• 668261-72-1 methyl 5-cyano-2-{[3-(piperidin-1-ylsulfonyl)benzoyl]amino}benzoate 
• 1174009-31-4 (3-(piperidin-1-ylsulfonyl)phenyl)methanol 
• 1004093-11-1 C₁₈H₁₉FN₂O₃S 
• 854167-08-1 3-(piperidin-1-ylsulfonyl)benzoyl chloride 
• 1016789-41-5 3-(piperidin-1-ylsulfonyl)benzonitrile 
• 361989-72-2 2-(3-(piperidin-1-ylsulfonyl)benzamido)benzoic acid 
• 1061858-26-1 methyl 2-(3-(piperidin-1-ylsulfonyl)benzamido)benzoate 
• 1192274-14-8 C₁₃H₂₀N₂O₂S 
• 1192233-48-9 C₁₃H₁₇NO₄S 
• 848813-81-0 C₁₂H₁₈N₂O₂S 
• 1192233-46-7 C₁₂H₁₆N₄O₂S 

Relevant academic research and scientific papers

Synthesis and Biological Evaluation of 4-Sulfamoylphenyl/Sulfocoumarin Carboxamides as Selective Inhibitors of Carbonic Anhydrase Isoforms hCA II, IX, and XII

With the aim to develop potent and selective human carbonic anhydrase inhibitors (hCAIs), we synthesized 4-sulfamoylphenyl/sulfocoumarin benzamides (series 5 a–r and series 7 a–q) and evaluated their inhibition profiles against five isoforms of the zinc-containing human carbonic anhydrase (hCA, EC 4.2.1.1): cytosolic hCA I and II, and the transmembrane isozymes hCA IV, IX, and XII. Compounds 5 a–r were found to selectively inhibit hCA II in the nanomolar range, while being less effective against the other hCA isoforms. As noted from the literature, sulfocoumarin (1,2-benzoxathiine 2,2-dioxide) acts as a “prodrug” inhibitor and is hydrolyzed by the esterase activity of hCA to form 2-hydroxyphenylvinylsulfonic acid, which thereafter binds to the enzyme in a manner similar to that of coumarins and sulfoxocoumarins. All these sulfocoumarins (compounds 7 a–q) were found to be very weak or ineffective as inhibitors of the housekeeping off-target hCA isoforms I and II, and effectively inhibited the transmembrane tumor-associated isoforms IX and XII in the high nanomolar to micromolar ranges. Further structural modifications of these molecules could be useful for the development of effective hCA inhibitors used for the treatment of glaucoma, epilepsy, and cancer.

FLT3 RECEPTOR ANTAGONISTS

The invention pertains to novel FLT3receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases.

Structure optimization of 2-benzamidobenzoic acids as PqsD inhibitors for Pseudomonas aeruginosa infections and elucidation of binding mode by SPR, STD NMR, and molecular docking

Pseudomonas aeruginosa employs a characteristic pqs quorum sensing (QS) system that functions via the signal molecules PQS and its precursor HHQ. They control the production of a number of virulence factors and biofilm formation. Recently, we have shown that sulfonamide substituted 2-benzamidobenzoic acids, which are known FabH inhibitors, are also able to inhibit PqsD, the enzyme catalyzing the last and key step in the biosynthesis of HHQ. Here, we describe the further optimization and characterization of this class of compounds as PqsD inhibitors. Structural modifications showed that both the carboxylic acid ortho to the amide and 3′-sulfonamide are essential for binding. Introduction of substituents in the anthranilic part of the molecule resulted in compounds with IC50 values in the low micromolar range. Binding mode investigations by SPR with wild-type and mutated PqsD revealed that this compound class does not bind into the active center of PqsD but in the ACoA channel, preventing the substrate from accessing the active site. This binding mode was further confirmed by docking studies and STD NMR.

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Compounds Having CRTH2 Antagonist Activity

Compounds of general formula (I) wherein W is chloro or fluoro; Z is a group SO2R1; wherein R1 is —C3-C8 cycloalkyl or heterocyclyl optionally substituted with one or more substituents chosen from hal

COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY

Compounds of general formula (I): wherein W is chloro or fluoro; Z is a group SO2R1; wherein R1 is -C3-C8 cycloalkyl or heterocyclyl optionally substituted with one or more substituents chosen from halo, -CN, -C1-C6 alkyl, -SOR3, -SO2R3, -SO2N(R2)2, -N(R2)2, -NR2C(O)R3, -CO2R2, -CONR2R3, -NO2, -OR2, -SR2, -O(CH2)POR2, and - O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, -Ci-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, -C1-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

THERAPEUTIC COMPOUNDS

The present invention provides novel compounds that function as potentiators of glutamate receptors, methods for their preparation, pharmaceutical compositions containing them, and methods of their use in therapy.